Get the Stockscreener App
16.05
3.95%
-0.66
Apollomics Inc stock is traded at $16.05, with a volume of 25,436.
It is down -3.95% in the last 24 hours and down -2.85% over the past month.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
See More
Previous Close:
$16.71
Open:
$16.85
24h Volume:
25,436
Relative Volume:
0.37
Market Cap:
$34.40M
Revenue:
-
Net Income/Loss:
$-53.86M
P/E Ratio:
-0.2947
EPS:
-54.4704
Net Cash Flow:
$-28.76M
1W Performance:
-1.35%
1M Performance:
-2.85%
6M Performance:
+131.94%
1Y Performance:
+107.36%
1-Day Range:
$16.00
$17.48
1-Week Range:
$15.61
$19.50
52-Week Range:
$3.659
$42.12
Apollomics Inc Stock (APLM) Company Profile
Compare APLM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLM
Apollomics Inc
|
16.05 | 35.82M | 0 | -53.86M | -28.76M | -54.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Apollomics Inc Stock (APLM) Latest News
Market Wrap: Will Apollomics Inc stock deliver shareholder valueWeekly Profit Recap & Expert Curated Trade Setups - BỘ NỘI VỤ
Book value per share of Apollomics Inc. Warrant 2023-01.04.28 on Apollomics – NASDAQ:APLMW - TradingView
Apollomics, LaunXP enter development, commercial agreement for Vebreltinib - MSN
How Apollomics Inc. Equity Warrant stock compares to industry benchmarksJuly 2025 Technicals & Verified Momentum Stock Watchlist - Newser
(APLM) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
APLM Stock Institutional Owners - Quiver Quantitative
Will Apollomics Inc. stock outperform tech sector in 2025Weekly Investment Recap & Smart Money Movement Tracker - Newser
How Apollomics Inc. Equity Warrant stock reacts to global recession fearsJuly 2025 Market Mood & High Yield Stock Recommendations - Newser
Apollomics (APLM) Stock Analysis Report | Financials & Insights - Benzinga
Why Apollomics Inc. stock could be next big winner2025 Top Decliners & Stepwise Swing Trade Plans - moha.gov.vn
Can Apollomics Inc. stock deliver surprise earnings beatPortfolio Gains Report & Risk Controlled Stock Alerts - BỘ NỘI VỤ
Will Apollomics Inc. Equity Warrant stock gain from lower inflationCEO Change & Low Drawdown Trading Techniques - moha.gov.vn
Apollomics Inc trading halted, volatility trading pause - MSN
Apollomics announces settlement of Cayman litigation - MSN
Will Apollomics Inc. Equity Warrant stock continue upward momentumPortfolio Performance Report & Accurate Technical Buy Alerts - newser.com
Leading vs lagging indicators on Apollomics Inc. Equity Warrant performanceQuarterly Earnings Summary & Target Return Focused Stock Picks - newser.com
Will Apollomics Inc. Equity Warrant stock beat EPS estimatesJuly 2025 Short Interest & Low Risk Growth Stock Ideas - newser.com
How supply chain issues affect Apollomics Inc. Equity Warrant stockPortfolio Risk Summary & Real-Time Market Sentiment Reports - newser.com
Apollomics Announces Settlement of Cayman Litigation - GlobeNewswire
Apollomics (Nasdaq: APLM) reaches Cayman settlement with $5M plus legal fees - Stock Titan
Apollomics entered settlement agreement related to legal proceedings by two minority investors of co - MarketScreener
[6-K] Apollomics Inc. Current Report (Foreign Issuer) | APLM SEC FilingForm 6-K - Stock Titan
Can Apollomics Inc. Equity Warrant stock resist sector downturnsEarnings Trend Report & Reliable Entry Point Trade Alerts - newser.com
Apollomics Inc. Equity Warrant’s volatility index tracking explainedJuly 2025 Earnings & Daily Stock Trend Reports - newser.com
How strong is Apollomics Inc. Equity Warrant stock revenue growth2025 Geopolitical Influence & Proven Capital Preservation Methods - newser.com
Is Apollomics Inc. Equity Warrant a candidate for recovery play2025 Market Trends & Low Risk High Win Rate Stock Picks - newser.com
What to do if you’re stuck in Apollomics Inc.Weekly Trend Summary & Technical Entry and Exit Alerts - newser.com
Apollomics Inc. Equity Warrant stock trendline breakdownPortfolio Risk Summary & Low Drawdown Momentum Trade Ideas - newser.com
Full technical analysis of Apollomics Inc. Equity Warrant stockMarket Sentiment Review & Real-Time Volume Trigger Notifications - newser.com
Published on: 2025-11-19 04:55:09 - newser.com
How Apollomics Inc. Equity Warrant stock reacts to bond yieldsTrade Analysis Report & Expert-Curated Trade Recommendations - newser.com
Exit strategy if you’re trapped in Apollomics Inc. Equity WarrantWeekly Trend Recap & AI Powered Trade Plan Recommendations - newser.com
Apollomics appoints Dr. Ya-Chi Huang to board following resignation - Investing.com India
Apollomics appoints Dr. Ya-Chi Huang to board following resignation By Investing.com - Investing.com Nigeria
Apollomics (Nasdaq: APLM) names Dr. Ya-Chi Huang to board, audit and governance roles - Stock Titan
Apollomics Announces Changes to its Board of Directors and Composition of Committees - Bluefield Daily Telegraph
What Fibonacci levels say about Apollomics Inc. reboundWeekly Trend Recap & Low Risk Profit Maximizing Plans - newser.com
Apollomics Inc Stock (APLM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):